Deadline Extended in Valeant Offer for ISTA (VRX, ISTA)
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Two weeks ago Valeant Pharmaceuticals International, Inc. (NYSE: VRX) made an unsolicited all-cash offer of $6.50/share for ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), a maker of eye-care drugs. The offer valued ISTA at around $327 million, including ISTA’s debt, a premium of 68% over ISTA’s most recent closing price.
ISTA has refused Valeant’s offer, calling it “grossly inadequate” but the two companies have been meeting to discuss a deal. Valeant’s original deadline to shareholders has been extended from January 12th to January 31st.
With ISTA shares trading above $7, Valeant is going to have to sweeten the deal if it expects to have a chance of acquiring ISTA.
Contact [email protected] for any questions or corrections.